ADC Therapeutics SA Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations
ADC Therapeutics SA (ADCT) reported Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations of $769.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-10.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations · last filed 2026-03-10
- ADC Therapeutics SA unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2025 was $769.00K, a 83.10% increase from fiscal 2024.
- ADC Therapeutics SA unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2024 was $420.00K, a 1300.00% increase from fiscal 2023.
- ADC Therapeutics SA unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2023 was $30.00K, a 25.00% increase from fiscal 2022.
- ADC Therapeutics SA unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2022 was $24.00K.
| Period end | Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations 12 month |
|---|---|
| 2025-12-31 | $769.00K 10-K · filed 2026-03-10 |
| 2024-12-31 | $420.00K 10-K · filed 2026-03-10 |
| 2023-12-31 | $30.00K 10-K · filed 2025-03-27 |
| 2022-12-31 | $24.00K 10-K · filed 2024-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |